June 26, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic a...
Read morePress releases
InDex Pharmaceuticals gets new patent in Europe
26 June 2019
- Regulatory press release
InDex Pharmaceuticals enrolls last patient in phase IIb study CONDUCT with cobitolimod
26 June 2019
- Regulatory press release
June 26, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that patient enrolment was completed in the dose optimisation study CONDUCT, which is evaluating cobitolimod for the treatment of moderate to severe ulcerative colitis. Top line results are expected to be available in 8...
Read moreInDex Pharmaceuticals presents at Redeye Growth Day on June 10, 2019
03 June 2019
- Other press release
...
Read moreInDex Pharmaceuticals presents at the Introduce Investor Days
23 May 2019
- Other press release
May 23, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at the Introduce Investor Days at Haymarket by Scandic in Stockholm on May 27 at 9.30 CET.
Read moreBulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
06 May 2019
- Regulatory press release
May 6, 2019 – The Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) took place on Monday, May 6, 2019 in the company´s premises at Tomtebodavägen 23a in Stockholm, Sweden.
Read moreInDex Pharmaceuticals Holding AB (publ) interim report January – March 2019
06 May 2019
- Regulatory press release
The final phase of the patient recruitment in the CONDUCT study
Read moreInDex Pharmaceuticals provides status update on the patient recruitment in the CONDUCT study
11 April 2019
- Regulatory press release
April 11, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that 197 patients, of the total 215 planned, have been enrolled to date in the CONDUCT study evaluating the drug candidate cobitolimod. The patient recruitment has varied significantly on a monthly basis, with between 6 and 19 p...
Read moreNotice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
05 April 2019
- Regulatory press release
April 5, 2019 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on Monday May 6, 2019 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.
Read moreInDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2018
02 April 2019
- Regulatory press release
April 2, 2019 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2018, which is earlier than indicated in the financial calendar. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, www.indexpharma.com.
Read moreInDex Pharmaceuticals Holding AB (publ) year end report 2018
20 February 2019
- Regulatory press release
Continued focus on the patient recruitment for the CONDUCT study
Read more